ALXO - ALX Oncology Holdings Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.72 -0.03 (-1.74%)	---	---	---	0.05 (2.69%)	-0.04 (-2.31%)	-0.02 (-1.16%)	0.04 (2.09%)

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -0.49
Diluted EPS:: -0.49
Basic P/E:: -3.449
Diluted P/E:: -3.449
RSI(14) 1m:: 45.45
VWAP:: 1.68
RVol:: 0.5235

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	1.67 -0.03 (-1.77%)	Oct 15 15:55
1m	Price increase 1m	1.69 +0.02 (+1.29%)	Oct 15 13:42
1m	Price increase 1m	1.73 +0.02 (+1.17%)	Oct 15 10:13
1m	Price increase 1m	1.74 +0.02 (+1.16%)	Oct 15 10:02
1m	Price increase 1m	1.74 +0.02 (+1.1%)	Oct 15 10:00